Michael J. Walsh
Independent Director

Mr. Walsh has served as a Director since June, 2014.  Mr. Walsh was most recently Executive Vice President, Chief Commercial Officer at Cypress Bioscience, Inc.  In this capacity, Mr. Walsh led the creation of a 115-person sales force and established commercial operations to support the launch of Savella (milnacipran), a pharmaceutical product for fibromyalgia, through a partnership with Forest Laboratories, Inc. as well as personalized medicine services focused in rheumatology.

Prior to Cypress, Mr. Walsh was the founder, Chairman and CEO of Proprius Pharmaceuticals, Inc., a specialty pharmaceutical and personalized medicine company focused in rheumatology and pain management, which was acquired by Cypress in 2008. Prior to Proprius, Mr. Walsh was co-founder and Executive Chairman at Prometheus Laboratories, where he also held the positions of President, Chief Operating Officer and Chief Executive Officer, from the founding of the company through late 2004. He is largely responsible for developing the company's unique strategy and business model, as well as leading its development into a profitable, integrated specialty pharmaceutical and clinical diagnostics company focused in gastroenterology. 

Prior to Prometheus, Mr. Walsh was with Quidel Corporation in a number of senior executive roles, including Director of Worldwide Marketing and Business Development, and Director of European Operations.  Prior to Quidel, he was Manager of Therapeutic Operations for La Jolla Pharmaceutical Company. 

Mr. Walsh has a Bachelor of Science degree from the University of Notre Dame and an M.B.A. from Pepperdine University.